Panelists discuss how patients and medical teams navigate the complex CAR T therapy journey, from initial referral through cell collection, manufacturing, and infusion, while highlighting crucial monitoring strategies for managing adverse effects such as cytokine release syndrome and neurotoxicity.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Since elacestrant’s emergence in the real-world setting, it has demonstrated superior efficacy outcomes compared with what the EMERALD study found.
Panelists discuss how the October 2024 FDA approval of inavolisib in combination with palbociclib and fulvestrant for HR positive (HR+)/ HER2 negative (HER2-) metastatic breast cancer with a PIK3CA mutation marks a pivotal advancement in precision medicine, highlighting how agents like such as inavolisib, capivasertib, elacestrant, and alpelisib have transformed treatment approaches and expanded therapeutic options for patients.
Panelists discuss how emerging targeted therapies, including novel PI3K inhibitors and combination treatments, are advancing precision pathways in HR positive (HR+)/HER2 negative (HER2-) breast cancer, offering new hope for personalized treatment and improved patient outcomes.
Panelists discuss recent clinical trial findings, including the PERSEUS, CASSIOPEIA, IsKia, and GMMG-HD7 studies, and how these evolving treatment strategies are shaping the approach to frontline therapy for patients with transplant-eligible multiple myeloma.
Objective response data from the CK-301-101 trial supports cosibelimab’s approval by the FDA, according to Jason J. Luke, MD, FACP.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Panelists discuss how using dual immunotherapy regimens for melanoma in real-world practice involves balancing efficacy with safety, patient comorbidities, and treatment accessibility, while also addressing challenges such as immune-related adverse events and treatment sequencing.
Panelists discuss key aspects of supportive care that aided a patient's journey, including the impact of her primary caregiver's support, the sources of strength drawn from personal, spiritual, or community connections, and the roles of integrative medicine and nutrition in her treatment experience.
Panelists discuss the supportive care considerations for patients being treated for metastatic HER2+ breast cancer, including the roles of nutrition, exercise, and other integrative approaches in enhancing patient well-being and treatment outcomes.
Panelists discuss how treating patients with melanoma and brain metastases requires a multidisciplinary approach, emphasizing the role of immunotherapy, targeted therapy, and local treatments, while considering factors like the extent of metastasis and patient-specific factors.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Panelists discuss how this patient was admitted after the day 1 dose of talquetamab for observation for CRS and ICANS. Patients such as this are given a 0.01-mg/kg dose on the first day, a 0.06-mg/kg dose on day 3, and a 0.04-mg/kg dose on day 5 if there are no issues. The patient is then monitored for 48 hours and is discharged before getting the 0.08-mg/kg dose.
Panelists discuss the chimeric antigen receptor (CAR) T-cell collection, manufacturing, and infusion process, highlighting how it differs from previous treatments, and share the challenges faced during CAR T-cell therapy, including managing adverse effects.
Panelists discuss how thoracic oncologists are adapting to a rapidly evolving treatment landscape for lung cancer, focusing on the integration of novel therapies and the importance of biomarker-driven approaches in patient care.
Panelists discuss how patient 1 is a 76-year-old female with unknown- stage R-ISS, oligosecretory IgG-K/KLC MM currently treated with talquetamab. One year following the talquetamab initiation, she is in VGPR/MRD- (likely CR or sCR as IFE positive is LLC and she has KLC). To spare toxicity physicians have decreased her dosing to monthly, starting with cycle 14 day 1.
Panelists discuss the rationale for considering chimeric antigen receptor (CAR) T-cell therapy in standard-risk multiple myeloma and how health care providers help patients understand and prepare for the decision to pursue CAR T-cell treatment.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Panelists discuss how a patient and their medical team collaborated to evaluate the differences between ide-cel and cilta-cel CAR T therapies to make an informed treatment decision.
Panelists discuss how clinical trial data from CARTITUDE-1, CARTITUDE-4, and KarMMa-3 demonstrate the efficacy of CAR T therapies cilta-cel and ide-cel in multiple myeloma, comparing their real-world outcomes and considering patient-specific factors for treatment selection.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
The 2 main pafolacianine components, a folate analog and a dye, are commonly used in other medical applications.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Panelists discuss the adverse effects experienced by a patient undergoing treatment with capecitabine (Xeloda), trastuzumab (Herceptin), and tucatinib (Tukysa), along with the strategies employed to manage those adverse effects, while also addressing patient follow-up procedures, including the frequency of visits, typical labs and imaging ordered, concerning symptoms and lab results, and the outcomes of the patient's most recent follow-up appointment.
Panelists discuss how dual immunotherapy for melanoma, including combinations like nivolumab plus ipilimumab or nivolumab plus relatlimab, requires careful consideration of sequencing decisions based on factors such as tumor burden, patient health status, and potential toxicity profiles.
Panelists discuss how patients are prepared for treatment, the adverse effects associated with different agents and combination regimens that they educate patients about, the process of administering treatment for HER2+ breast cancer, and the overall approach to monitoring and managing adverse effects throughout the treatment journey.
Panelists discuss how the indirect treatment comparison of RELATIVITY-047 and CheckMate 067 suggests that nivolumab plus relatlimab may provide similar efficacy to nivolumab plus ipilimumab in advanced melanoma, with a potentially better safety profile.
Panelists discuss how unmet needs in glioma treatment persist despite recent advances, highlighting key areas for future research and development to improve outcomes and quality of life for patients with gliomas.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
